Ambitious Smaller Companies Hunt Big Prey as Bold M&A Returns
The improving environment for deals is encouraging some smaller firms to start hunting much larger prey.Most Read from ...
Cytek Biosciences downgraded to Sell from Buy at Goldman Sachs
Goldman Sachs analyst Matthew Sykes double downgraded Cytek Biosciences (CTKB) to Sell from Buy with a price target of $4.50, down from $7. The ...